Company

Dart NeuroScience

As of the edition of 20 October 2026, Dart NeuroScience runs 5 drugs; it is on route A at 5 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Dart NeuroScience was dissolved.

  • Dart NeuroScience, LLC: dissolved

Drugs by status

StatusCount
Went quiet2
Stopped3
Total5

Where it needs a new molecule

Route A at 5 targets, route B at 0 targets.

Three of its 5 rows, by target and route
TargetRoute
PDE4B 3',5'-cyclic-AMP phosphodiesterase 4BRoute A
PDE4A 3',5'-cyclic-AMP phosphodiesterase 4ARoute A
PDE4C 3',5'-cyclic-AMP phosphodiesterase 4CRoute A

All 5 rows on route A or B

In the product

5 company-target rows on route A or B; 2 are not shown here, and no score is.

Where its trials are

  • Nervous system: 3 trials led
  • Heart and blood vessels: 2 trials led
  • Ear, nose and throat: 1 trials led